Newron and Zambon consent to ink an agreement for pivotal study with safinamide in Parkinson’s disease patients
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical organization zeroed in on the improvement of novel treatments for
Read more